Press Releases


Media Contact:
Stephen Majors
Director, Public Affairs
smajors@alliancerm.org


Media Contact:
Stephen Majors
Director, Public Affairs
smajors@alliancerm.org

ARM Statement on Cures 2.0 Discussion Draft

June 22, 2021

WASHINGTON, DC

ARM commends Reps. Upton and DeGette for their continued leadership in driving scientific innovation and patient access. The Cures 2.0 discussion draft released today would help accelerate the development and delivery of life-changing cell and gene therapies. Harnessing real-world evidence, providing educational programming and training for caregivers, and requiring the FDA to provide more clarity around CMC standards for breakthrough and RMAT-designated therapies would help bring the future of medicine to patients in need.


Alliance for Regenerative Medicine Launches Internship Program for Black Students

June 17, 2021

Washington, DC

Created to address the underrepresentation of Black employees in the regenerative medicine workforce, the Alliance for Regenerative Medicine (ARM) launched the GROW RegenMed Internship Program this month with 17 interns in its inaugural class. GROW interns, who are undergraduate and graduate students, are working in paid positions at ARM and 13 of its member organizations this summer in a variety of roles, from the lab to regulatory affairs and public policy.


German Parliament Approves Legislation to Accelerate Access to Life-Changing Cell and Gene Therapies

June 15, 2021

BRUSSELS, BELGIUM

Legislation approved by the German Parliament on 11 June would accelerate patient access to transformative cell and gene therapies by addressing a bureaucratic barrier that delayed their availability in hospitals.

The reduction of the “NUB gap” – advocated for by the Alliance for Regenerative Medicine (ARM), its member organizations, and the Association for German University Hospitals (VUD) – would enable NUB inquiries to occur twice a year for Advanced Therapy Medicinal Products (ATMPs) instead of just once. Inquiries could also be made before market authorization of a therapy.


Alliance for Regenerative Medicine, European Federation of Pharmaceutical Industries and Associations, and European Association for Bioindustries Call for Advanced Therapies to be Exempt from EU GMO Legislation

May 25, 2021

BRUSSELS, BELGIUM

The European Commission should exempt advanced therapies from Genetically Modified Organism (GMO) legislation, which hurts Europe’s ability to attract clinical trials and delays patient access to transformative medicines, said the Alliance for Regenerative Medicine (ARM), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the European Association of Bioindustries (EuropaBio) in a paper published online yesterday in the journal Human Gene Therapy.